A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery

Bone tumor surgery is associated with a significant risk of perioperative blood loss, with blood loss usually in the range of approximately 500-1000 ml. The postoperative anemia caused by blood loss is an independent risk factor for postoperative complications in patients undergoing bone tumor surgery, as well as affecting the long-term survival rate of cancer patients.

Acute normovolemic hemodilution (ANH) is a patient blood management measure. The clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. As goal-directed fluid therapy (GDFT) is increasingly used in clinical practice, it is of great importance to explore the efficacy of ANH in patients undergoing fluid management using GDFT.

Bone tumor surgery is an ideal setting to evaluate ANH in GDFT, as the procedure is associated with high blood loss and infusion. This trial has been designed as a randomized, controlled trial to determine whether ANH will improve postoperative hemoglobin levels when applying GDFT in patients undergoing bone tumor surgery.

Inclusion criteria

• age 18 to 75 years;
• undergoing elective bone tumor resection surgery;
• preoperative hemoglobin ≥11 g/dL;

Exclusion criteria

• using a tourniquet;
• palliative operation or minimally invasive surgery;
• BMI<18.5 or >30Kg/m^2;
• international normalized ratio (INR) >1.5 or platelet count <100 × 10^9/L;
• cardiopulmonary insufficiency;
• hepatic and renal dysfunction;
• active infectious disease;
• allergy to succinyl gelatin;
• pregnancy;
• declined participation in the study or declined blood transfusion